The success of GLP-1 medications for treating Type 2 diabetes and obesity naturally leads to a related question: Do GLP-1 drugs affect cancer risk, which is often associated with obesity and Type 2 diabetes?
With a new grant from the National Institutes of Health, the University of Oklahoma Health Stephenson Cancer Center is growing its mission of building the next generation of health professionals.